InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: tradero post# 251071

Sunday, 01/31/2016 9:08:49 AM

Sunday, January 31, 2016 9:08:49 AM

Post# of 346056
1/3 of 80% =155

Great post tradero and very helpful. I am still surprised to hear about the 1/3 of 80% vs 1/3 of 100% and I was not sure if that is typical of other trial designs or maybe Peregrine was able to leverage this into Sunrise. I am becoming very intrigued on trial designs and I think "biomarkers" will be included in Peregrines list of surprises. Very interesting times ahead....

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News